Kumthekar Anand, Ogdie Alexis
Montefiore Medical Center, Albert Einstein College of Medicine, New York, NY, USA.
University of Pennsylvania, Philadelphia, PA, USA.
Rheumatol Ther. 2020 Sep;7(3):447-456. doi: 10.1007/s40744-020-00215-6. Epub 2020 Jun 3.
Patients with psoriatic arthritis (PsA) have a higher burden of cardio-metabolic comorbidities like obesity, hypertension, diabetes, and cardiovascular disease compared to the general population. Adipose tissue is thought to promote a chronic low grade inflammatory state through inflammatory mediators like tumor necrosis factor alpha (TNFα), interleukin-6 (IL-6), leptin, and adiponectin. A higher body mass index (BMI) is a risk factor for development of PsA and affects disease activity and response to therapy including both disease-modifying anti-rheumatic drugs (DMARDs) and tumor necrosis factor inhibitors (TNFi). Obesity has an impact on the morbidity in PsA, particularly cardiovascular and/or metabolic. Patients with PsA have a higher cardiovascular risk and obesity may have an additive impact on morbidity and mortality. This review explores the relationship between obesity and PsA.
与普通人群相比，银屑病关节炎（PsA）患者患肥胖、高血压、糖尿病和心血管疾病等心血管代谢合并症的负担更高。脂肪组织被认为通过肿瘤坏死因子α（TNFα）、白细胞介素-6（IL-6）、瘦素和脂联素等炎症介质促进慢性低度炎症状态。较高的体重指数（BMI）是PsA发病的危险因素，并影响疾病活动以及对包括改善病情抗风湿药（DMARDs）和肿瘤坏死因子抑制剂（TNFi）在内的治疗的反应。肥胖对PsA的发病率有影响，尤其是心血管和/或代谢方面。PsA患者有较高的心血管风险，肥胖可能对发病率和死亡率产生叠加影响。本综述探讨肥胖与PsA之间的关系。
